Abstract
Purpose Unpredictable chemotherapy side effects are a major barrier to successful treatment. Cell culture and mouse experiments indicate that the gut microbiota is influenced by and influences anti-cancer drugs. However, metagenomic data from patients paired to careful side effect monitoring remains limited. Herein, we focus on the oral fluoropyrimidine capecitabine (CAP). We investigate CAP-microbiome interactions through metagenomic sequencing of longitudinal stool sampling from a cohort of advanced colorectal cancer (CRC) patients.
Methods We established a prospective cohort study including 56 patients with advanced CRC treated with CAP monotherapy across 4 centers in the Netherlands. Stool samples and clinical questionnaires were collected at baseline, during cycle 3, and post-treatment. Metagenomic sequencing to assess microbial community structure and gene abundance was paired with transposon mutagenesis, targeted gene deletion, and media supplementation experiments. An independent US cohort was used for model validation.
Results CAP treatment significantly altered gut microbial composition and pathway abundance, enriching for menaquinol (vitamin K2) biosynthesis genes. Transposon library screens, targeted gene deletions, and media supplementation confirmed that menaquinol biosynthesis protects Escherichia coli from drug toxicity. Microbial menaquinol biosynthesis genes were associated with decreased peripheral sensory neuropathy. Machine learning models trained in this cohort predicted hand-foot syndrome and dose reductions in an independent cohort.
Conclusion These results suggest treatment-associated increases in microbial vitamin biosynthesis serve a chemoprotective role for bacterial and host cells, with implications for toxicities outside the gastrointestinal tract. We provide a proof-of-concept for the use of microbiome profiling and machine learning to predict drug toxicities across independent cohorts. These observations provide a foundation for future human intervention studies, more in-depth mechanistic dissection in preclinical models, and extension to other cancer treatments.
Competing Interest Statement
LEH, JZ, and MLS have received research funding from Danone Global Research & Innovation Center, outside the submitted work. Additionally, MLS, RA, and JVG have received funding from Servier, and MLS from Illumina, all outside the submitted work. JVG has served as a consultant for Amgen, AstraZeneca, MSD, Pierre Fabre, and Servier, all outside the submitted work. JP has received research funding from Friesland Campina outside the submitted work. WAK has received research funding (institution) from Pfizer; there is no direct overlap with the current study. PJT is on the scientific advisory boards of Pendulum, Seed and SNIPRbiome; there is no direct overlap between the current study and these consulting duties. CEA has received research funding (institution) from Bristol Meyer Squibb, Erasca, Guardant Health, Merck and Novartis and has served on Scientific Advisory Boards for Roche/Genentech, Sumitomo, and the Colorectal Cancer Alliance; there is no direct overlap with the current study. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Funding Statement
Funding was provided from the National Institutes of Health (R01CA255116, R01DK114034, and R01HL122593 to P.J.T.) and Stichting Jules Coenegracht Sr (to M.L.S.). P.J.T is a Chan Zuckerberg Biohub-San Francisco Investigator.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Medical Ethics Committee azM/UM (METC 16-4-234.1) and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All raw sequencing data with human reads removed have been deposited to the NCBI Sequence Read Archive (SRA) and are accessible via BioProject PRJNA1169175. Processed datasets and all original code used in this study is available on GitHub (https://github.com/turnbaughlab/2024_Trepka_DrugToxicity).
